Published in Int J Clin Exp Med on July 15, 2010
The effect of bariatric surgeries on nonalcoholic fatty liver disease. Saudi J Gastroenterol (2014) 1.39
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol (2012) 1.27
Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon (2013) 1.09
Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis (2013) 0.99
In vivo application of short-lag spatial coherence imaging in human liver. Ultrasound Med Biol (2013) 0.93
What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol (2012) 0.89
Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation. Int J Clin Exp Pathol (2010) 0.85
Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. PLoS One (2013) 0.82
The effect of berberis vulgaris extract on transaminase activities in non-alcoholic Fatty liver disease. Hepat Mon (2015) 0.81
Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD). Hepatobiliary Surg Nutr (2015) 0.79
A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid. Ups J Med Sci (2010) 0.77
Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution. J Ultrasound (2016) 0.75
Prevalence and sonographic changes compatible with fatty liver disease in patients referred for abdominal ultrasound examination in Aracaju, SE. Radiol Bras (2016) 0.75
Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index. Gastroenterology Res (2015) 0.75
The Wide and Complex Field of NAFLD Biomarker Research: Trends. ISRN Hepatol (2014) 0.75
Undernutrition, risk of malnutrition and obesity in gastroenterological patients: A multicenter study. World J Gastrointest Oncol (2016) 0.75
The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc (2016) 0.75
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 10.88
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol (2006) 4.52
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Nonalcoholic steatohepatitis. Semin Liver Dis (2004) 2.89
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol (2007) 2.48
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol (2005) 2.21
The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol (1999) 2.18
Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol (2009) 1.88
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int (2006) 1.73
Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol (2007) 1.65
Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol (2006) 1.56
Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology (2001) 1.51
Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol (2007) 1.41
Impact of smoking on histological liver lesions in chronic hepatitis C. Gut (2003) 1.40
Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol (2007) 1.37
Prevalence of obesity in primary care using different anthropometric measures--results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). BMC Public Health (2008) 1.13
Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2006) 1.10
Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol (2009) 1.07
Effects of diffuse fatty infiltration of the liver on portal vein flow hemodynamics. J Clin Ultrasound (2008) 1.05
Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme (1986) 0.94
Portal vein hemodynamics in patients with non-alcoholic fatty liver disease. Tohoku J Exp Med (2008) 0.93
Relationship of smoking and fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2006) 0.91
VAT fat is bad for the liver, SAT fat is not! J Gastroenterol Hepatol (2008) 0.89
Visceral fat thickness predicts fatty liver in Koreans with type 2 diabetes mellitus. J Korean Med Sci (2008) 0.81
Perihepatic adipose tissue thickness: a new non-invasive marker of NAFLD? J Gastrointestin Liver Dis (2009) 0.80
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) (2007) 3.33
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med (2009) 2.55
Adipocytokines in synovial fluid. JAMA (2003) 2.48
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2004) 2.45
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Intensive care unit alarms--how many do we need? Crit Care Med (2010) 2.29
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology (2010) 2.11
Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2005) 2.06
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol (2007) 1.88
DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol (2011) 1.85
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol (2010) 1.82
Ultrasound-guided sacroiliac joint injection in patients with established sacroiliitis: precise IA injection verified by MRI scanning does not predict clinical outcome. Rheumatology (Oxford) (2009) 1.80
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood (2004) 1.76
Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol (2006) 1.74
Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology (2014) 1.73
Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol (2010) 1.73
The potential of adiponectin in driving arthritis. J Immunol (2006) 1.70
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int (2011) 1.63
Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis (2008) 1.61
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 1.60
Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol (2005) 1.60
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med (2009) 1.59
Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J Rheumatol (2004) 1.58
Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) (2009) 1.57
Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J Gastroenterol Hepatol (2008) 1.56
Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab (2007) 1.56
HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol (2003) 1.55
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol (2005) 1.53
Innate immunity and adipose tissue biology. Trends Immunol (2010) 1.50
Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood (2004) 1.49
Screening for osteoporosis in patients with inflammatory bowel disease by using urinary N-telopeptides. Eur J Gastroenterol Hepatol (2002) 1.48
Ablation of the sympathetic nervous system decreases gram-negative and increases gram-positive bacterial dissemination: key roles for tumor necrosis factor/phagocytes and interleukin-4/lymphocytes. J Infect Dis (2005) 1.48
Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis (2010) 1.47
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Collection of annotated data in a clinical validation study for alarm algorithms in intensive care--a methodologic framework. J Crit Care (2009) 1.46
Cardiac arrest: composition of resuscitation teams and training techniques: results of a hospital survey in German-speaking countries. Dtsch Arztebl Int (2009) 1.44
Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum (2002) 1.36
GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets (2009) 1.34
Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol (2004) 1.32
Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res (2003) 1.30
CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol (2002) 1.30
Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut (2010) 1.29
Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. Int J Colorectal Dis (2005) 1.28
The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab Invest (2008) 1.27
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol (2005) 1.26
CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology (2005) 1.25
Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum (2002) 1.24
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23
Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol (2009) 1.22
Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res (2009) 1.20
The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Lett (2005) 1.19
Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology (2013) 1.18
Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol (2010) 1.18
Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol (2013) 1.18
Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol (2012) 1.17
Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.16
Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis (2006) 1.15
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis (2009) 1.14
Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism (2007) 1.14
Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep (2006) 1.14
miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol (2012) 1.13
Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab (2010) 1.13
Effects of the new adiponectin paralogous protein CTRP-3 and of LPS on cytokine release from monocytes of patients with type 2 diabetes mellitus. Cytokine (2009) 1.13
Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1. FASEB J (2010) 1.13
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer (2009) 1.12
Iron-induced expression of bone morphogenic protein 6 in intestinal cells is the main regulator of hepatic hepcidin expression in vivo. Gastroenterology (2009) 1.11
Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis (2010) 1.11
TNFalpha is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Commun (2008) 1.11
Increased prevalence of semaphorin 3C, a repellent of sympathetic nerve fibers, in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum (2004) 1.10
Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis (2005) 1.09
Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen. J Neuroimmunol (2003) 1.08
Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One (2012) 1.08
Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol (2009) 1.08
Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol (2009) 1.07
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med (2005) 1.07
Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis (2003) 1.07
Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol (2005) 1.07
Abdominal MRI after enteroclysis or with oral contrast in patients with suspected or proven Crohn's disease. Clin Gastroenterol Hepatol (2004) 1.07
The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol (2007) 1.06
13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells. Biochem Pharmacol (2007) 1.06
A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol (2008) 1.05
Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci (2007) 1.05
Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis. World J Gastroenterol (2009) 1.05